Impact of HbA1c, Followed From Onset of Type 1 Diabetes, on the Development of Severe Retinopathy and Nephropathy: The VISS Study (Vascular Diabetic Complications in Southeast Sweden)
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: HbA1c is strongly related to the development of diabetes complications, but it is still controversial which HbA1c level to strive for in the treatment of type 1 diabetes. The aim of the current study was to evaluate HbA1c, followed from diagnosis, as a predictor of severe microvascular complications and to formulate HbA1c target levels for treatment. RESEARCH DESIGN AND METHODS: A longitudinal observation study followed an unselected population of 451 patients diagnosed with type 1 diabetes during 1983–1987 before the age of 35 years in a region of Southeast Sweden. Retinopathy was evaluated by fundus photography and nephropathy data collected from medical records. HbA1c was measured starting from diagnosis and during the whole follow-up period of 20–24 years. Long-term weighted mean HbA1c was then calculated. Complications were analyzed in relation to HbA1c levels. RESULTS: The incidence of proliferative retinopathy and persistent macroalbuminuria increased sharply and occurred earlier with increasing long-term mean HbA1c. None of the 451 patients developed proliferative retinopathy or persistent macroalbuminuria below long-term weighted mean HbA1c 7.6% (60 mmol/mol); 51% of the patients with long-term mean HbA1c above 9.5% (80 mmol/mol) developed proliferative retinopathy and 23% persistent macroalbuminuria. CONCLUSIONS: Long-term weighted mean HbA1c, measured from diagnosis, is closely associated with the development of severe complications in type 1 diabetes. Keeping HbA1c below 7.6% (60 mmol/mol) as a treatment target seems to prevent proliferative retinopathy and persistent macroalbuminuria for up to 20 years.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, the CKD-EPI equation has been updated to a new version that is race agnostic and termed CKD-EPI 2021.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [396]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Analysis of serial measurements in medical research.
Matthews, J. N., Altman, D. G., Campbell, M. J., & Royston, P. (1990) · BMJ · doi:10.1136/bmj.300.6719.230 · Cited by 3,136
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study
Andersen, A. R., Christiansen, J. S., Andersen, J. K., Kreiner, S., & Deckert, T. (1983) · Diabetologia · doi:10.1007/bf00284458 · Cited by 1,067
The Glycosylation of Hemoglobin: Relevance to Diabetes Mellitus
Bunn, H. F., Gabbay, K. H., & Gallop, P. M. (1978) · Science · doi:10.1126/science.635569 · Cited by 876
Renal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791
Hoelzel, W., Weykamp, C., Jeppsson, J.-O., Miedema, K., Barr, J. R., Goodall, I., Hoshino, T., John, W. G., Kobold, U., Little, R., et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.024802 · Cited by 690
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Diabetes Control and Complications Trial (DCCT) Research Group (1996) · Diabetes · doi:10.2337/diab.45.10.1289 · Cited by 597
Declining Incidence of Nephropathy in Insulin-Dependent Diabetes Mellitus
Bojestig, M., Arnqvist, H. J., Hermansson, G., Karlberg, B. E., & Ludvigsson, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401063300103 · Cited by 453
Self-citationKrolewski, A. S., Laffel, L. M. B., Krolewski, M., Quinn, M., & Warram, J. H. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505113321902 · Cited by 452
Chaturvedi, N., Porta, M., Klein, R., Orchard, T., Fuller, J., Parving, H. H., Bilous, R., & Sjølie, A. K. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61412-9 · Cited by 451
Epidemiologic Approach to the Etiology of Type I Diabetes Mellitus and Its Complications
Flier, J. S., Underhill, L. H., Krolewski, A. S., Warram, J. H., Rand, L. I., & Kahn, C. R. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711263172206 · Cited by 417
Dahl-Jorgensen, K., Brinchmann-Hansen, O., Hanssen, K. F., Ganes, T., Kierulf, P., Smeland, E., Sandvik, L., & Aagenaes, O. (1986) · BMJ · doi:10.1136/bmj.293.6556.1195 · Cited by 329
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
Fullerton, B., Jeitler, K., Seitz, M., Horvath, K., Berghold, A., & Siebenhofer, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009122.pub2 · Cited by 299
Feldt-Rasmussen, B., Mathiesen, E. R., Jensen, T., Lauritzen, T., & Deckert, T. (1991) · Diabetologia · doi:10.1007/bf00418270 · Cited by 222
Glycation and oxidation: A role in the pathogenesis of atherosclerosis
Lyons, T. J. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90142-y · Cited by 221
Nordwall, M., Bojestig, M., Arnqvist, H. J., & Ludvigsson, J. (2004) · Diabetologia · doi:10.1007/s00125-004-1431-6 · Cited by 216
Self-citationRossing, P., Hommel, E., Smidt, U. M., & Parving, H. H. (1994) · Diabetologia · doi:10.1007/s001250050140 · Cited by 192
Risk for ESRD in Type 1 Diabetes Remains High Despite Renoprotection
Rosolowsky, E. T., Skupien, J., Smiles, A. M., Niewczas, M., Roshan, B., Stanton, R., Eckfeldt, J. H., Warram, J. H., & Krolewski, A. S. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010040354 · Cited by 191
Kofoed-Enevoldsen, A., Borch-Johnsen, K., Kreiner, S., Nerup, J., & Deckert, T. (1987) · Diabetes · doi:10.2337/diab.36.2.205 · Cited by 190
Leure‐Dupree, A. E. (1981) · PubMed · Cited by 156
Reichard, P., Pihl, M., Rosenqvist, U., & Sule, J. (1996) · Diabetologia · doi:10.1007/s001250050602 · Cited by 152
Antihypertensive agents for preventing diabetic kidney disease
Lv, J., Perkovic, V., Foote, C. V., Craig, M. E., Craig, J. C., & Strippoli, G. F. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004136.pub3 · Cited by 148
Nordwall, M., Arnqvist, H. J., Bojestig, M., & Ludvigsson, J. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00472.x · Cited by 110
Self-citationLeiter, L. A. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.015 · Cited by 105
Danne, T., Weber, B., Hartmann, R., Enders, I., Burger, W., & Hovener, G. (1994) · Diabetes Care · doi:10.2337/diacare.17.12.1390 · Cited by 93
Glycemic Control and Prognosis in Type I Diabetic Patients With Microalbuminuria
Bojestig, M., Arnqvist, H. J., Karlberg, B. E., & Ludvigsson, J. (1996) · Diabetes Care · doi:10.2337/diacare.19.4.313 · Cited by 76
Self-citationGlycosylated Hemoglobin and the Risk of Retinopathy in Insulin-Dependent Diabetes Mellitus
Warram, J. H., Manson, J. E., & Królewski, A. S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505113321915 · Cited by 73
Comparisons of Studies on Diabetic Complications Hampered by Differences in GHb Measurements
Kullberg, C. E., Bergström, A., Dinesen, B., Larsson, L., Little, R. R., Goldstein, D. E., & Arnqvist, H. J. (1996) · Diabetes Care · doi:10.2337/diacare.19.7.726 · Cited by 59
Self-citationTreviño, G. (2007) · Diabetes Care · doi:10.2337/dc07-1752 · Cited by 47
Kullberg, C. E., Abrahamsson, M., Arnqvist, H. J., Finnström, K., & Ludvigsson, J. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00839.x · Cited by 47
Self-citationBenefits of Renin-Angiotensin Blockade on Retinopathy in Type 1 Diabetes Vary With Glycemic Control
Harindhanavudhi, T., Mauer, M. S., Klein, R., Zinman, B., Sinaiko, A. R., Caramori, M. L., & for the Renin Angiotensin System Study (RASS) group (2011) · Diabetes Care · doi:10.2337/dc11-0476 · Cited by 43
Glucose control in diabetes: which target level to aim for?
Laakso, M., & Cederberg, H. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02528.x · Cited by 29
Reviewing statin therapy in diabetes—Towards the best practise
Matikainen, N., Kahri, J., & Taskinen, M. (2010) · Primary care diabetes · doi:10.1016/j.pcd.2010.01.005 · Cited by 20
Hirose, A., Furushima, D., Yamaguchi, N., Kitano, S., & Uchigata, Y. (2013) · Diabetes Care · doi:10.2337/dc13-0532 · Cited by 18
Pre-pubertal onset of type 1 diabetes and appearance of retinopathy
Porta, M., Dalmasso, P., Grassi, G., Marena, S., Maurino, M., Passera, P., & Trento, M. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70113-1 · Cited by 12
Research works printed but not linked: 1
- 2007, Diabetes Care
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence
Simó, R., & Hernández, C. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.04.003 · Cited by 239
“6% (60 mmol/mol) as a treatment target seems to prevent PDR for up to 20 years in type 1 diabetic patients (Nordwall et al., 2015).”
BackgroundInfluentialDiabetic Retinopathy in the Context of Patients with Diabetes
Simó-Servat, O., Hernández, C., & Simó, R. (2019) · Ophthalmic Research · doi:10.1159/000499541 · Cited by 233
Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies
Rodríguez, M. L., Pérez, S., Mena-Mollá, S., Desco, M. C., & Ortega, Á. L. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/4940825 · Cited by 222
“6% (60mmol/mol), it seems to prevent proliferative DR for up to 20 years in T1DM patients [24].”
BackgroundLind, M., Pivodic, A., Svensson, A.-M., Ólafsdóttir, A. F., Wedel, H., & Ludvigsson, J. (2019) · BMJ · doi:10.1136/bmj.l4894 · Cited by 175
Self-citation
Metadata
- Authors
- Nordwall, M., Abrahamsson, M., Dhir, M., Fredrikson, M., Ludvigsson, J., & Arnqvist, H. J.
- Affiliations
- Linköping University (SE)
- Corresponding author
- Nordwall, Maria
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-12-15
- Volume
- 38
- Issue
- 2
- Pages
- 308-315
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2095970617
- Cited by
- 161
- References
- 41
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 15 · 2023: 13 · 2022: 16 · 2021: 8 · 2020: 19 · 2019: 13 · 2018: 16 · 2017: 20 · 2016: 15 · 2015: 13
- FWCI
- 12.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- HbA1c, type 1 diabetes, proliferative diabetic retinopathy, diabetic nephropathy, macroalbuminuria, microvascular complications, glycemic targets, long-term glycemic control
- MeSH terms
- Adolescent, Adult, Aged, Child, Diabetes Mellitus, Type 1, Diabetic Angiopathies, Diabetic Nephropathies, Diabetic Retinopathy, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Middle Aged, Sweden, Incidence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.